[{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Precision For Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase III","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Diagnostics \/ Precision For Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Blue Earth Diagnostics \/ Precision For Medicine"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Precision For Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase III","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Diagnostics \/ Precision For Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Blue Earth Diagnostics \/ Precision For Medicine"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Innovate UK | Syne Qua Non Limited | IND 2 Results","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2015","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase III","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Earth Diagnostics \/ Innovate UK | Syne Qua Non Limited | IND 2 Results","highestDevelopmentStatusID":"10","companyTruncated":"Blue Earth Diagnostics \/ Innovate UK | Syne Qua Non Limited | IND 2 Results"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"American College of Radiology | IND 2 Results | Syne Qua Non Limited","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2016","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase III","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Earth Diagnostics \/ American College of Radiology | IND 2 Results | Syne Qua Non Limited","highestDevelopmentStatusID":"10","companyTruncated":"Blue Earth Diagnostics \/ American College of Radiology | IND 2 Results | Syne Qua Non Limited"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase II","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Diagnostics \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"8","companyTruncated":"Blue Earth Diagnostics \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase II","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Diagnostics \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"8","companyTruncated":"Blue Earth Diagnostics \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase II","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Diagnostics \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"8","companyTruncated":"Blue Earth Diagnostics \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2019","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase II","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Earth Diagnostics \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"8","companyTruncated":"Blue Earth Diagnostics \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2019","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase I","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Diagnostics \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"6","companyTruncated":"Blue Earth Diagnostics \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase I","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Earth Diagnostics \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"6","companyTruncated":"Blue Earth Diagnostics \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Radiolabeled Compound","year":"2019","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase I","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Diagnostics \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"6","companyTruncated":"Blue Earth Diagnostics \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Radiolabeled Compound","year":"2019","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase I","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Blue Earth Diagnostics \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"6","companyTruncated":"Blue Earth Diagnostics \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Radiolabeled Compound","year":"2017","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase II","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Blue Earth Diagnostics \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"8","companyTruncated":"Blue Earth Diagnostics \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Radiolabeled Compound","year":"2018","type":"Inapplicable","leadProduct":"18-F Fluciclovine","moa":"Amino acid transporter","graph1":"Oncology","graph2":"Phase IV","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Earth Diagnostics \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"11","companyTruncated":"Blue Earth Diagnostics \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2019","type":"Inapplicable","leadProduct":"F-Fluciclovine","moa":"Amino acid transporters","graph1":"Oncology","graph2":"Phase II","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Earth Diagnostics \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"8","companyTruncated":"Blue Earth Diagnostics \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"UNII-38R1Q0L1ZE","moa":"Amino acid transporters","graph1":"Oncology","graph2":"Phase IV","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Diagnostics \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"11","companyTruncated":"Blue Earth Diagnostics \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Abiraterone Acetate","moa":"Cytochrome P450 17A1","graph1":"Oncology","graph2":"Phase II","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Earth Diagnostics \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"8","companyTruncated":"Blue Earth Diagnostics \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2017","type":"Inapplicable","leadProduct":"18-F FLT","moa":"DNA synthesis","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Earth Diagnostics \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"7","companyTruncated":"Blue Earth Diagnostics \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Aixial Group","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"18-F Flotufolastat","moa":"PSMA","graph1":"Oncology","graph2":"Phase IV","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Earth Diagnostics \/ Aixial Group","highestDevelopmentStatusID":"11","companyTruncated":"Blue Earth Diagnostics \/ Aixial Group"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2024","type":"Inapplicable","leadProduct":"18-F rhPSMA-7.3","moa":"PSMA","graph1":"Oncology","graph2":"Phase II","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Earth Diagnostics \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"8","companyTruncated":"Blue Earth Diagnostics \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Hackensack Meridian Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"18-F rhPSMA-7.3","moa":"PSMA","graph1":"Oncology","graph2":"Undisclosed","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blue Earth Diagnostics \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"1","companyTruncated":"Blue Earth Diagnostics \/ Blue Earth Diagnostics"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Recombinant Human PSMA-7.3","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Diagnostics \/ Parexel","highestDevelopmentStatusID":"10","companyTruncated":"Blue Earth Diagnostics \/ Parexel"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Parexel","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Recombinant Human PSMA-7.3","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Diagnostics \/ Parexel","highestDevelopmentStatusID":"10","companyTruncated":"Blue Earth Diagnostics \/ Parexel"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Recombinant Human PSMA-7.3","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Diagnostics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Blue Earth Diagnostics \/ Undisclosed"},{"orgOrder":0,"company":"Blue Earth Diagnostics","sponsor":"Blue Earth Diagnostics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Recombinant Human PSMA-7.3 (18F)","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Blue Earth Diagnostics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Blue Earth Diagnostics \/ Blue Earth Diagnostics","highestDevelopmentStatusID":"10","companyTruncated":"Blue Earth Diagnostics \/ Blue Earth Diagnostics"}]

Find Clinical Drug Pipeline Developments & Deals by Blue Earth Diagnostics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : 18-F rhPSMA-7.3 is a Radiolabelled Compounds drug candidate, which is currently being evaluated in clinical studies for the treatment of Prostatic Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Radiolabeled Compound

                          Upfront Cash : Inapplicable

                          June 08, 2025

                          Lead Product(s) : 18-F rhPSMA-7.3

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Recipient : Hackensack Meridian Health

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : 18-F rhPSMA-7.3 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Prostatic Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Radiolabeled Compound

                          Upfront Cash : Inapplicable

                          September 27, 2024

                          Lead Product(s) : 18-F rhPSMA-7.3

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : AdventHealth

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : 18-F Flotufolastat is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Prostatic Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Radiolabeled Compound

                          Upfront Cash : Inapplicable

                          September 19, 2024

                          Lead Product(s) : 18-F Flotufolastat

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase IV

                          Sponsor : Aixial Group

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : 18-F Fluciclovine is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Prostatic Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Radiolabeled Compound

                          Upfront Cash : Inapplicable

                          October 02, 2023

                          Lead Product(s) : 18-F Fluciclovine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : Brigham and Women's Hospital

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : 18-F Fluciclovine is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Brain Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Radiolabeled Compound

                          Upfront Cash : Inapplicable

                          September 21, 2023

                          Lead Product(s) : 18-F Fluciclovine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : Baptist Health

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Recombinant Human PSMA-7.3 (18F) is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Prostatic Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          April 05, 2023

                          Lead Product(s) : Recombinant Human PSMA-7.3 (18F)

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Recipient : MidLantic Urology

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : 18-F Fluciclovine is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Brain Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Radiolabeled Compound

                          Upfront Cash : Inapplicable

                          September 26, 2022

                          Lead Product(s) : 18-F Fluciclovine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : Baptist Health

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : 18-F Fluciclovine is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Brain Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Radiolabeled Compound

                          Upfront Cash : Inapplicable

                          December 30, 2020

                          Lead Product(s) : 18-F Fluciclovine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : Baptist Health

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : 18-F Fluciclovine is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Brain Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Radiolabeled Compound

                          Upfront Cash : Inapplicable

                          June 01, 2020

                          Lead Product(s) : 18-F Fluciclovine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Precision For Medicine

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : 18-F Fluciclovine is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Brain Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Radiolabeled Compound

                          Upfront Cash : Inapplicable

                          June 01, 2020

                          Lead Product(s) : 18-F Fluciclovine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Precision For Medicine

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank